EUVIMEDEUVIMED entdecken
EditorialKommentar

Cardiovascular burden of narcolepsy: what have we learned and what do we still need to know?

Lucie Barateau, Yves Dauvilliers iD

SLEEP · 11.10.2023 · 46 (10)

DOI: 10.1093/sleep/zsad213 ↗

Kurz gefasst

Editorial in der Zeitschrift SLEEP, online erschienen am 16.08.2023. Verfasst von Lucie Barateau und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, Montpellier, France. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Narcolepsy is a rare central disorder of hypersomnolence characterized by excessive daytime sleepiness that can be associated with cataplexy, hypnagogic/hypnopompic hallucinations, sleep paralysis, and disrupted nighttime sleep. Two forms of narcolepsy are identified: narcolepsy type 1 (NT1, formerly named narcolepsy with cataplexy) caused by a loss of orexinergic/hypocretinergic neurons in the hypothalamus and low cerebrospinal (CSF) orexin levels; and narcolepsy type 2 (NT2, formerly named narcolepsy without cataplexy) sometimes associated with partial loss of orexin neurons, but most often associated with normal CSF orexin levels and therefore of unknown pathophysiology [1]. The orexin system is involved in the central regulation of several basic functions, including the sleep–wake cycles but also the autonomic control (e.g. heart rate and blood pressure), thermoregulation, and energy homeostasis. NT1 is associated with clinical autonomic dysfunction, daytime hypertension, and a frequent lack of nocturnal blood pressure dipping [2–4], a phenomenon linked to mortality in the general population [5, 6]. Surprisingly, patients with NT1 had lower resting sympathetic and cardiovascular activities, assessed by direct microneurographic monitoring of muscle sympathetic nerve activity during wakefulness [7]. Also, patients with NT1 are often obese (30%–50%), with a weight gain especially in childhood and at disease onset [8, 9], with diabetes type 2, metabolic syndrome [10, 11], depression [12], and other sleep disorders (e.g. sleep apnea, periodic leg movements), which further increase their cardiovascular risk [3]. However, as key limitations, these results often come for small sample sizes, cross-sectional studies, mainly in NT1, and in patients often treated with wake-promoting agents (e.g. modafinil/armodafinil, solriamfetol, pitolisant, methylphenidate, and amphetamines), sodium oxybate and antidepressants/anticataplectic (e.g. venlafaxine, clomipramine, and fluoxetine) drugs. Most of these life-long medications, often used in both narcolepsy types, can affect the autonomic nervous system, especially by increasing heart rate and blood pressure [13]. Thus, causal links between Narcolepsy (NT1/NT2) and cardiovascular disorders were difficult to establish. More recently, patients with narcolepsy, without individualization of NT1 versus NT2, from different US-population-based analyses were reported to be associated with an increased risk of cardiovascular disorders (myocardial infarction, cardiac arrest, heart failure, and stroke) and an albeit controversial risk of increased mortality rate [11, 14, 15].

Autor:innen und Institutionen

  • Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, Montpellier, France.
  • National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome, Montpellier, France.
  • INM, Univ Montpellier, INSERM, Montpellier, France.

ORCID-Profile: Yves Dauvilliers

Zitieren

APA

Barateau, L., & Dauvilliers, Y. (2023). Cardiovascular burden of narcolepsy: what have we learned and what do we still need to know?. SLEEP, 46(10). https://doi.org/10.1093/sleep/zsad213

Vancouver

Barateau L, Dauvilliers Y. Cardiovascular burden of narcolepsy: what have we learned and what do we still need to know?. SLEEP. 2023;46(10). doi:10.1093/sleep/zsad213

BibTeX
@article{Barateau2023,
  author = {Barateau, Lucie and Dauvilliers, Yves},
  title = {Cardiovascular burden of narcolepsy: what have we learned and what do we still need to know?},
  journal = {SLEEP},
  year = {2023},
  volume = {46},
  number = {10},
  doi = {10.1093/sleep/zsad213}
}
Kostenlos starten →